Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | PAM | P19021 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986474 | 1.00 | IDO1 (0.52) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL9777486 | 0.80 | IDO1 (0.58) | IDO1PAMMAOBHTR2ANPC1 | |
| SCHEMBL4863423 | 0.80 | IDO1 (0.58) | IDO1PAMMAOBHTR2ANPC1 | |
| SCHEMBL7939387 | 0.78 | IDO1 (0.56) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL7568412 | 0.78 | IDO1 (0.56) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL10430031 | 0.78 | IDO1 (0.56) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL29030882 | 0.76 | IDO1 (0.54) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL19284235 | 0.76 | IDO1 (0.54) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| Cinnamic Alcohol SCHEMBL4175503 | 0.74 | PAM (0.58) | IDO1PAMMAOBHTR2A | |
| SCHEMBL17769273 | 0.74 | IDO1 (0.52) | IDO1PAMMAOBHTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351743-B1 | Therapeutic guanidines | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070265348-A1 | N-(4-sec-butylphenyl)-N-benzylguanidine; modulate, particularly inhibit, the release of neurotransmitter such as glutamate; neurodegenerative disease: Parkinson's, Huntington's, Alzheimer's diseases, Amyotrophic Lateral Sclerosis, Down's Syndrome, epilepsy, atrophy, HIV | SCION PHARMACEUTICALS, INC, A DELAWARE CORPORATION | 2007-11-15 | — | — | US | disclosed |
| US-6787569-B1 | INHIBITORS OF NEUROTRANSMITTER (E.G., GLUTAMATE) RELEASE FROM ISCHEMIC NEURONAL CELLS; N,N-DISUBSTITUTED GUANIDINES; NEUROLOGICAL CONDITIONS SUCH AS EPILEPSY, NEURODEGENERATIVE CONDITIONS AND/OR NERVE CELL DEATH FROM STROKE OR HEART ATTACK | CAMBRIDGE NEUROSCIENCE, INC. | 2004-09-07 | — | — | US | disclosed |
| US-6288123-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCES, INC. | 2001-09-11 | — | — | US | disclosed |
| US-6174924-B1 | Therapeutic guanidines | CAMBRIDGE NEUROSCIENCE, INC. | 2001-01-16 | — | — | US | disclosed |
| US-6143791-A | NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| EP-0751767-A4 | THERAPEUTIC GUANIDINES | CAMBRIDGE NEUROSCIENCE INC (US) | 1997-12-10 | — | — | EP | disclosed |
| EP-0751767-A1 | THERAPEUTIC GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995020950-A1 | THERAPEUTIC GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| US-5422360-A | Hydrazonoimidazolidin-4-one derivatives; treatment of diabetes and aging disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-06 | — | — | US | disclosed |
| EP-0531812-A1 | Maillard reaction inhibitor, process for producing it, composition containing it and the use thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265348-A1 | N-(4-sec-butylphenyl)-N-benzylguanidine; modulate, particularly inhibit, the release of neurotransmitter such as glutamate; neurodegenerative disease: Parkinson's, Huntington's, Alzheimer's diseases, Amyotrophic Lateral Sclerosis, Down's Syndrome, epilepsy, atrophy, HIV | GAP43, NLN, HTT | IDO1 2245/4885PAM 3919/4885MAOB 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.